Press release
Ischemic Heart Disease (IHD) Drugs Market Outlook 2024-2033 - Market Research Analysis, Trends, Demand
"The Business Research Company recently released a comprehensive report on the Global Ischemic Heart Disease (IHD) Drugs Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, the ischemic heart disease (ihd) drugs market size has grown strongly in recent years. It will grow from $6.02 billion in 2023 to $6.36 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to rising global prevalence of ischemic heart disease, increased awareness and diagnostics, changes in lifestyle and dietary patterns, government initiatives for cardiovascular health, collaborations for clinical trials, insurance coverage and reimbursement policies..
The ischemic heart disease (ihd) drugs market size is expected to see steady growth in the next few years. It will grow to $7.57 billion in 2028 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to aging population trends, personalized medicine approaches, emphasis on cardiovascular prevention, global health policies and initiatives, international research collaborations.. Major trends in the forecast period include shift towards precision medicine approaches, focus on novel anti-atherogenic agents, advancements in lipid-lowering therapies, integration of anti-inflammatory agents, development of antithrombotic and antiplatelet drugs..
Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report
Market Drivers and Trends:
The growing prevalence of obesity and diabetes is expected to propel the growth of the ischemic heart disease (IHD) drugs market going forward. Diabetes is a long-term metabolic disease that causes high blood glucose levels, and obesity is a medical condition characterized by an excessive accumulation of body fat that can negatively impact health. Ischemic heart disease drugs are often used in individuals with obesity and diabetes to manage cardiovascular risk factors such as hypertension and dyslipidemia, mitigating the risk of ischemic heart disease. For instance, in March 2023, according to the World Obesity Federation, a UK-based not-for-profit organization, by 2035, obesity rates are expected to double among boys, reaching 208 million (a 100% increase), and more than double among girls, totaling 175 million (a 125% increase), as reported from 2020 levels. Further, It is estimated that the number of people living with obesity will reach 2.7 billion by 2025. Furthermore, in December 2021, according to the International Diabetes Federation, a US-based intergovernmental organization, diabetes affected 537 million adults (20-79 years old) in 2021, and it is predicted that the number would climb to 643 million people by 2030 and a total of 783 million by 2045. Therefore, the growing prevalence of obesity and diabetes drives the growth of the ischemic heart disease (IHD) drugs market.
Major companies operating in the ischemic heart disease (IHD) drugs market are increasing their focus on developing innovative platelet inhibitors, such as intravenous P2Y12 platelet inhibitors, to gain a competitive edge in the market. An intravenous P2Y12 platelet inhibitor is a medication administered directly into the bloodstream to prevent platelet activation and aggregation and reduce the risk of periprocedural myocardial infarction (MI), an ischemic heart disease. For instance, in October 2021, MSN Laboratories Private Limited, an India-based research-based pharmaceutical company, launched CANREAL injection (Cangrelor), the only intravenous P2Y12 platelet inhibitor with rapid onset and offset of platelet inhibition. It was developed to overcome both delayed and prolonged antiplatelet activity. It is a bioequivalent generic drug that is indicated as an adjunct to percutaneous coronary intervention to reduce the risk of myocardial infarction (MI).
Key Benefits for Stakeholders:
• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp
Major Key Players of the Market:
Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC
Ischemic Heart Disease (IHD) Drugs Market 2024 Key Insights:
• The ischemic heart disease (ihd) drugs market is expected to grow to $7.57 billion in 2028 at a compound annual growth rate (CAGR) of 4.4%.
• Rising Prevalence Of Obesity And Diabetes Fuels Expansion Of The Ischemic Heart Disease (IHD) Drugs Market
• Increasing Focus On Developing Intravenous P2Y12 Platelet Inhibitor To Gain A Competitive Advantage
• North America was the largest region in the ischemic heart disease (IHD) drugs market in 2023
We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=13467&type=smp"
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
"Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide."
According to The Business Research Company's, the ischemic heart disease (ihd) drugs market size has grown strongly in recent years. It will grow from $6.02 billion in 2023 to $6.36 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to rising global prevalence of ischemic heart disease, increased awareness and diagnostics, changes in lifestyle and dietary patterns, government initiatives for cardiovascular health, collaborations for clinical trials, insurance coverage and reimbursement policies..
The ischemic heart disease (ihd) drugs market size is expected to see steady growth in the next few years. It will grow to $7.57 billion in 2028 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to aging population trends, personalized medicine approaches, emphasis on cardiovascular prevention, global health policies and initiatives, international research collaborations.. Major trends in the forecast period include shift towards precision medicine approaches, focus on novel anti-atherogenic agents, advancements in lipid-lowering therapies, integration of anti-inflammatory agents, development of antithrombotic and antiplatelet drugs..
Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report
Market Drivers and Trends:
The growing prevalence of obesity and diabetes is expected to propel the growth of the ischemic heart disease (IHD) drugs market going forward. Diabetes is a long-term metabolic disease that causes high blood glucose levels, and obesity is a medical condition characterized by an excessive accumulation of body fat that can negatively impact health. Ischemic heart disease drugs are often used in individuals with obesity and diabetes to manage cardiovascular risk factors such as hypertension and dyslipidemia, mitigating the risk of ischemic heart disease. For instance, in March 2023, according to the World Obesity Federation, a UK-based not-for-profit organization, by 2035, obesity rates are expected to double among boys, reaching 208 million (a 100% increase), and more than double among girls, totaling 175 million (a 125% increase), as reported from 2020 levels. Further, It is estimated that the number of people living with obesity will reach 2.7 billion by 2025. Furthermore, in December 2021, according to the International Diabetes Federation, a US-based intergovernmental organization, diabetes affected 537 million adults (20-79 years old) in 2021, and it is predicted that the number would climb to 643 million people by 2030 and a total of 783 million by 2045. Therefore, the growing prevalence of obesity and diabetes drives the growth of the ischemic heart disease (IHD) drugs market.
Major companies operating in the ischemic heart disease (IHD) drugs market are increasing their focus on developing innovative platelet inhibitors, such as intravenous P2Y12 platelet inhibitors, to gain a competitive edge in the market. An intravenous P2Y12 platelet inhibitor is a medication administered directly into the bloodstream to prevent platelet activation and aggregation and reduce the risk of periprocedural myocardial infarction (MI), an ischemic heart disease. For instance, in October 2021, MSN Laboratories Private Limited, an India-based research-based pharmaceutical company, launched CANREAL injection (Cangrelor), the only intravenous P2Y12 platelet inhibitor with rapid onset and offset of platelet inhibition. It was developed to overcome both delayed and prolonged antiplatelet activity. It is a bioequivalent generic drug that is indicated as an adjunct to percutaneous coronary intervention to reduce the risk of myocardial infarction (MI).
Key Benefits for Stakeholders:
• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp
Major Key Players of the Market:
Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC
Ischemic Heart Disease (IHD) Drugs Market 2024 Key Insights:
• The ischemic heart disease (ihd) drugs market is expected to grow to $7.57 billion in 2028 at a compound annual growth rate (CAGR) of 4.4%.
• Rising Prevalence Of Obesity And Diabetes Fuels Expansion Of The Ischemic Heart Disease (IHD) Drugs Market
• Increasing Focus On Developing Intravenous P2Y12 Platelet Inhibitor To Gain A Competitive Advantage
• North America was the largest region in the ischemic heart disease (IHD) drugs market in 2023
We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=13467&type=smp"
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
"Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide."
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage
to this press release on woodPRI. woodPRI disclaims liability for any content contained in
this release.
Recommend
/newsMicroencapsulation Market Deep Analysis on Key Players - Dow Corning, Encapsys, Syngenta Crop Protection, Evonik Industries, 3M and Bayer
Market Study Report Adds Global Microencapsulation Market Size, Status and Forecast 2024 added to its database. The report provides key statistics on the current state of the industry and other analytical data to understand the market.
Extensive research is required for choosing the appropriate cor...
/newsGermany Airbag Market Size 2023: Global Share, Industry And Report Analysis By 2030 | Hyundai Mobis Co., Ltd. Key Safety Systems, Inc. Robert Bosch GmbH
Germany airbag market is expected to grow at a CAGR of around 6% during the forecast period. Germany Airbag Market research report refers to gathering and analyzing significant market data serve as best medium for various industry players to launch novel product or service. It is vital for key firms...
/newsSecurities Brokerages And Stock Exchanges Market Outlook 2021: Big Things are Happening
A new intelligence report released by HTF MI with title "Global Securities Brokerages And Stock Exchanges Market Survey & Outlook" is designed covering micro level of analysis by Insurers and key business segments, offerings and sales channels. The Global Securities Brokerages And Stock Exchange...
/newsRenewable Chemicals Market Emerging Trends and Competitive Landscape Forecast to 2028
The renewable chemicals market was valued at US$ 80,566.30 million in 2021 and is projected to reach US$ 1,76,750.76 million by 2028 it is expected to grow at a CAGR of 11.9% from 2021 to 2028. The research report focuses on the current market trends, opportunities, future potential of the market, a...
/newsHow Coronavirus is Impacting Cold Brew Coffee, Global Market Volume Analysis, Size, Share and Key Trends 2020-2026
"Market Latest Research Report 2020:
Los Angles United States, February 2020: The Cold Brew Coffee market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Research's lates...
/newsCorporate E-Learning Market - Global Industry Size, Share, Key Players Analysis that are Infor, SkillSoft Corporation, Adrenna, CERTPOINT Systems and others with Regional Forecast to 2022
Overview:
E-Learning is used to enhance the learning procedures for newer job requirements and to make employees sound about the internal and external changes in the market and respective organizations. This method has created considerable differences in the ways of training and developing employee...
